X0306 4 2022-07-05 0 0000891293 CTI BIOPHARMA CORP CTIC 0001507220 Metzger Michael A 3101 WESTERN AVENUE SUITE 800 SEATTLE WA 98121 1 0 0 0 common stock 2022-07-05 4 M 0 91500 0.8411 A 111621 D common stock 2022-07-05 4 S 0 8700 5.9766 D 102921 D common stock 2022-07-05 4 S 0 51963 6.0512 D 50958 D common stock 2022-07-05 4 S 0 27506 6.1403 D 23452 D common stock 2022-07-05 4 S 0 3331 6.2255 D 20121 D Non-Qualified Stock Option (right to buy) 0.8411 2022-07-05 4 M 0 91500 0 D 2029-05-16 Common Stock 91500 28500 D This sale was effected pursuant to a 10b5-1 sales plan adopted by the Reporting Person. Reflects sales of common stock executed in multiple transactions at prices ranging from $ 5.95 to $ 5.99. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.00 to $ 6.10. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.11 to $ 6.20. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. Reflects sales of common stock executed in multiple transactions at prices ranging from $ 6.21 to $ 6.25. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. The shares underlying the option were fully vested on May 16, 2020, the date that is twelve months after the date of grant. /s/ Bruce Seeley, attorney-in-fact for Michael A. Metzger 2022-07-07